


REMARKS

Applicants believe that no new matter is introduced in the filing of this Preliminary Amendment. Applicants respectfully request examination of the above-named application in view of the present amendments.

Respectfully submitted,

HUNTON & WILLIAMS



Robert M. Schulman
Registration No. 31,196
Jeffrey T. Perez
Prov. Reg. No. 52,110

1900 K Street, N.W., Suite 1200
Washington, D.C. 20006-1109
Tel: (202) 955-1928
Fax: (202) 778-2201

Dated: August 19, 2002

Attachment A - Redline Version of Claims

1. (Amended) A composition comprising:
a polypeptide; and
an active agent covalently attached to said polypeptide, wherein said active agent is an analgesic.
2. (Amended) The composition of claim 1 wherein said ~~active agent~~ analgesic is selected from the group consisting of ABT 594, Acetaminophen, Acetaminophen with Codeine phosphate, Acetaminophen and hydrocodone bitartrate, Acetaminophen with Propoxyphene napsylate, Acetylsalicylic acid, Butorphanol tartrate, carisoprodol and codeine, CD11a (Efalizumab), celecoxib, Codeine, Diacetylmorphine, Dihydrocodeine, Dihydromorphine, etanercept, Ethylmorphine, Etoricoxib, Fentanyl, Hydrocodone, Hydromorphone, Hydromorphone HCl, Ibuprofen and hydrocodone, Ketorolac, leflunomide (for arthritis), Methyldihydromorphinone, Morphine Sulfate, Oxycodone HCl, Oxycodone/APAP, Oxymorphone, pentosan polysulfate sodium, rofecoxib, Propoxyphene Napsylate/APAP, 4030W92, Tramadol HCl, and Tramadol/APAP, ~~the compounds listed in TABLE 1.~~
3. (Amended) The composition of claim 1-2 wherein said polypeptide is a homopolymer of a naturally occurring amino acid.
4. (Amended) The composition of claim 1-2 wherein said polypeptide is a heteropolymer of two or more naturally occurring amino acids.
5. (Amended) The composition of claim 1-2 wherein said polypeptide is a homopolymer of a synthetic amino acid.
6. (Amended) The composition of claim 1-2 wherein said polypeptide is a heteropolymer of two or more synthetic amino acids.
7. (Amended) The composition of claim 1-2 wherein said polypeptide is a heteropolymer of one or more naturally occurring amino acids and one or more synthetic amino acids.
8. (Amended) The composition of claim 1-2 wherein said active agent is covalently attached to a side chain, the N-terminus or the C-terminus of said polypeptide.

9. ~~(Canceled)~~ The composition of claim 1 wherein said active agent is a carboxylic acid and wherein said active agent is covalently attached to the N-terminus of said polypeptide.

10. ~~(Canceled)~~ The composition of claim 1 wherein said active agent is an amine and wherein said active agent is covalently attached to the C-terminus of said polypeptide.

11. ~~(Canceled)~~ The composition of claim 1 wherein said active agent is an alcohol and wherein said active agent is covalently attached to the C-terminus of said polypeptide.

12. ~~(Canceled)~~ The composition of claim 1 wherein said active agent is an alcohol and wherein said active agent is covalently attached to the N-terminus of said polypeptide.

13. (Amended) The composition of claim 1-2 further comprising a microencapsulating agent.

14. The composition of claim 13 wherein said microencapsulating agent is selected from the group consisting of polyethylene glycol (PEG), an amino acid, a sugar and a salt.

15. (Amended) The composition of claim 1-2 further comprising an adjuvant.

16. The composition of claim 15 wherein said adjuvant activates an intestinal transporter.

17. (Amended) The composition of claim 1-2 further comprising a pharmaceutically acceptable excipient.

18. ~~(Canceled)~~ The composition of claim 1 wherein said active agent is a nutrient and said composition is a nutraceutical composition.

19. ~~(Canceled)~~ The composition of claim 1 wherein said active agent is a pharmaceutical agent and said composition is a pharmaceutical composition.

20. (Amended) The composition of claim 1-2 wherein said composition is in the form of an ingestible tablet.

21. (Amended) The composition of claim 1-2 wherein said composition is in the form of an intravenous preparation.

22. (Amended) The composition of claim 1-2 wherein said composition is in the form of an oral suspension.

23. (Amended) The composition of claim 1-2 wherein said active agent is conformationally protected by folding of said polypeptide about said active agent.

24. (Amended) The composition of claim 1-2 wherein said polypeptide is capable of releasing said active agent from said composition in a pH-dependent manner.

25. (Amended) A method for protecting an ~~active agent~~analgesic from degradation comprising covalently attaching said active agent to a polypeptide.

26. (Amended) A method for controlling release of an ~~active agent~~analgesic from a composition wherein said composition comprises a polypeptide, said method comprising covalently attaching said active agent to said polypeptide.

27. (Amended) A method for delivering an ~~active agent~~analgesic to a patient comprising administering to said patient a composition comprising:

a polypeptide; and

an active agent covalently attached to said polypeptide.

28. (Amended) The method of claim 27 wherein said ~~active agent~~analgesic is released from said composition by an enzyme-catalyzed release.

29. (Amended) The method of claim 28 wherein said ~~active agent~~analgesic is released in a time-dependent manner based on the pharmacokinetics of said enzyme-catalyzed release.

30. (Amended) The method of claim 27 wherein said composition further comprises a microencapsulating agent and wherein said ~~active agent~~analgesic is released from said composition by dissolution of said microencapsulating agent.

31. (Amended) The method of claim 27 wherein said ~~active agent~~analgesic is released from said composition by a pH-dependent unfolding of said polypeptide.

32. (Amended) The method of claim 27 wherein said ~~active agent~~analgesic is released from said composition in a sustained release.

33. The method of claim 27 wherein said composition further comprises an adjuvant covalently attached to said polypeptide and wherein release of said adjuvant from said composition is controlled by said polypeptide.

34. (Amended) A method for preparing a composition comprising a polypeptide and an ~~active agent~~analgesic covalently attached to said polypeptide, said method comprising the steps of:

(a) attaching the ~~active agent~~analgesic to a side chain of an amino acid to form an ~~active agent~~analgesic/amino acid complex;

(b) forming an ~~active agent~~analgesic/amino acid complex N-carboxyanhydride (NCA) from said ~~active agent~~analgesic/amino acid complex; and

(c) polymerizing said ~~active agent~~analgesic/amino acid complex N-carboxyanhydride (NCA).

35. (Canceled) The method of claim 34 wherein the ~~active agent is a pharmaceutical agent or an adjuvant.~~

36. The method of claim 34 wherein steps (a) and (b) are repeated prior to step (c) with a second active agent.

37. (Amended) The method of claim ~~35-36~~ wherein said active agent and said second active agent are copolymerized in step (c).

38. (Amended) The method of claim 34 wherein said amino acid is glutamic acid and wherein said ~~active agent~~analgesic is released from said glutamic acid as a dimer upon a hydrolysis of the polypeptide and wherein said ~~active agent~~analgesic is released from said glutamic acid by coincident intramolecular transamination.

39. (Amended) The method of claim 38 wherein said glutamic acid is ~~replaced by an~~ amino acid selected from the group consisting of aspartic acid, arginine, asparagine, cysteine, lysine, threonine, and serine, and wherein said ~~active agent~~ analgesic is attached to the side chain of the amino acid to form an amide, a thioester, an ester, an ether, a urethane, a carbonate, an anhydride or a carbamate.

40. (Amended) The method of claim 38 wherein said glutamic acid is ~~replaced by a~~ synthetic amino acid with a pendant group comprising an amine, an alcohol, a sulfhydryl, an amide, a urea, or an acid functionality.

41. (New) A composition comprising:
a polypeptide; and
an active agent covalently attached to said polypeptide, wherein said active agent is an anti-anxiety drug.

42. (New) The composition of claim 41 wherein said anti-anxiety drug is selected from the group consisting of Alprazolam, Buspirone, Clonazepam, Clorazepate, Chlordiazepoxide, diazepam, lesopitron, Lorazepam, Oxazepam, pagoclon and pregabalin.

43. (New) A composition comprising:
a polypeptide; and
an active agent covalently attached to said polypeptide, wherein said active agent is an antiarrhythmic.

44. (New) The composition of claim 43 wherein said antiarrhythmic is selected from the group consisting of adenosine and Amiodarone.

45. (New) A composition comprising:
a polypeptide; and
an active agent covalently attached to said polypeptide, wherein said active agent is an antibiotic.

46. (New) The composition of claim 45 wherein said antibiotic is selected from the group consisting of ABT 773, Amoxicillin, amoxicillin with clavulanate potassium,

Azithromycin dihydrate, BPI 21, Cefaclor, Cefadroxil, Cefadroxil hemihydrate, Cefazolin sodium, Cefdinir, Cefixime, Cefotaxime sodium, Cefotetan disodium, Cefoxitin sodium, Cefpodoxime proxetil, Cefprozil, Ceftazidime, Ceftibuten dihydrate, Cefuroxime axetil, Cefuroxime sodium, Cephalexin, CS 834, Imipenem, ciprofloxacin, clarithromycin, Erythromycin, , Erythromycin/Sulfisoxazole, Gentamycin, Gentamycin Isoton, BMS 284756 (garenoxacin), Levofloxacin, Loracarbef, Meropenem, MK 826, Metronidazole, Minocycline HCl, nitrofurantoin, nitrofurantoin macrocrystalline, norfloxacin, ofloxacin, penicillin, penicillin V, Piperacillin sodium, sitafloxacin, tetracycline, Tobramycin sulfate, tifacogin, trovafloxacin mesylate, and Vancomycin HCl.

47. (New) A composition comprising:

_____ a polypeptide; and

an active agent covalently attached to said polypeptide, wherein said active agent is an anticoagulant.

48. (New) The composition of claim 47 wherein said anticoagulant is selected from the group consisting of activated protein C, Acetylsalicylic acid, dalteparin sodium, enoxaparin sodium, heparin, and Warfarin Sodium.

49. (New) A composition comprising:

_____ a polypeptide; and

an active agent covalently attached to said polypeptide, wherein said active agent is an antidepressant.

50. (New) The composition of claim 49 wherein said antidepressant is selected from the group consisting of Amitriptyline HCl, Bupropion HCl, citalopram hydrobromide, duloxetine, Fluoxetine, Fluvoxamine maleate, gepirone hydrochloride, Imipramine HCl, mirtazapine, nefazodone hydrochloride, Nortriptyline HCl, paroxetine hydrochloride, sertraline hydrochloride, Trazadone HCl, and venlafaxine hydrochloride.

51. (New) A composition comprising:

_____ a polypeptide; and

an active agent covalently attached to said polypeptide, wherein said active agent is a drug for treating diabetes.

52. (New) The composition of claim 51 wherein said drug for treating diabetes is selected from the group consisting of acarbose, exendin-4, glimepiride, Glipizide, Glyburide, Metfomin, mitiglinide, pioglitazone hydrochloride, repaglinide, rosiglitazone maleate, and troglitazone.

53. (New) A composition comprising:

_____ a polypeptide; and

an active agent covalently attached to said polypeptide, wherein said active agent is an antidiarrhea agent.

54. (New) The composition of claim 53 wherein said antidiarrhea agent is selected from ecadotril, octreotide acetate, and Loperamide HCl.

55. (New) A composition comprising:

_____ a polypeptide; and

an active agent covalently attached to said polypeptide, wherein said active agent is an antiemetic.

56. (New) The composition of claim 55 wherein said antiemetic is selected from the group consisting of cilansetron, dolasetron mesylate monohydrate, granisetron hydrochloride, itasetron, ondansetron hydrochloride, Prochlorperazine maleate, Promethazine HCl, and 5-HT3-antagonist.

57. (New) A composition comprising:

_____ a polypeptide; and

an active agent covalently attached to said polypeptide, wherein said active agent is an antiepileptic.

58. (New) The composition of claim 57 wherein said antiepileptic is selected from the group consisting of carbamazepine, divalproex sodium, fosphenytoin sodium, Gabapentin, ganaxolone, lamotrigine, Phenytoin sodium, Primidone, tiagabine hydrochloride, and topiramate.

59. (New) A composition comprising:

_____ a polypeptide; and

an active agent covalently attached to said polypeptide, wherein said active agent is an antifungal.

60. (New) The composition of claim 59 wherein said antifungal is selected from the group consisting of caspofungin, fluconazole, Itraconazole, Ketoconazole, FK 463, posaconazole, terbinafine hydrochloride, and voriconazole.

61. (New) A composition comprising:

_____ a polypeptide; and

an active agent covalently attached to said polypeptide, wherein said active agent is an antigout.

62. (New) The composition of claim 61 wherein said antigout is Allopurinol.

63. (New) A composition comprising:

_____ a polypeptide; and

an active agent covalently attached to said polypeptide, wherein said active agent is an antihistamine.

64. (New) The composition of claim 63, wherein said antihistamine is selected from the group consisting of Astemizole, azelastine hydrochloride, cetirizine hydrochloride, ciclesonide, Cimetidine, chlorpheniramine, desloratidine, diphenhydramine, fexofenadine hydrochloride, levocetirizine, loratadine, norastemizole, cimetidine, famotidine, nizatidine, and ranitidine.

65. (New) A composition comprising:

_____ a polypeptide; and

an active agent covalently attached to said polypeptide, wherein said active agent is an antiinflammatory.

66. (New) The composition of claim 65 wherein said antiinflammatory is selected from the group consisting of aspirin, diclofenac, diclofenac/misoprostol, fluticasone, Ibuprofen, Ketoprofen, mesalamine, nabumetone, Naproxen sodium, tepoxalin, valdecoxib, Etodolac, Oxaprozin, and the steroid drugs listed under immunosuppressants.

67. (New) A composition comprising:

_____ a polypeptide; and

an active agent covalently attached to said polypeptide, wherein said active agent is an antimalarial.

68. (New) The composition of claim 67 wherein said antimalarial is selected from the group consisting of atovaquone, mefloquine hydrochloride, and Hydroxychloroquine sulfate.

69. (New) A composition comprising:

_____ a polypeptide; and

an active agent covalently attached to said polypeptide, wherein said active agent is an antimigraine.

70. (New) The composition of claim 69 wherein said antimigraine is selected from the group consisting of dapitant, Ergotamine Tartrate, methysergide, naratriptan hydrochloride, rizatriptan benzoate, sumatriptan, and zolmitriptan.

71. (New) A composition comprising:

_____ a polypeptide; and

an active agent covalently attached to said polypeptide, wherein said active agent is an antineoplastic.

72. (New) The composition of claim 71 wherein said antineoplastic is selected from the group consisting of anastrozole, antisense oligonucleotide, bicalutamide, bleomycin, capecitabine, carboplatin, , cisplatin, Cyclophosphamide, Docetaxel, doxorubicin hydrochloride, dutasteride, edodekin alfa, eniluracil, Etoposide, fenretinide, Fluorouracil, Flutamide, gemcitabine hydrochloride, Idarubicin HCl, interleukin-2, irinotecan hydrochloride, LYM 1, marimastat, Mercaptopurine, mitoxantrone hydrochloride, nelarabine, paclitaxel, pemetrexed, prinomastat, rubitecan, satraplatin, sparfosic acid, tamoxifen citrate, Thiotepa, tirapazamine, Topotecan HCl, trastuzumab, valspodar and vinorelbine tartrate.

73. (New) A composition comprising:

_____ a polypeptide; and

an active agent covalently attached to said polypeptide, wherein said active agent is an antipsychotic.

74. (New) The composition of claim 73 wherein said antipsychotic is selected from the group consisting of anastrozole, antisense oligonucleotides, aripiprazole, clozapine, haloperidol, olanzapine, quetiapine, and risperidone.

75. (New) A composition comprising:

_____ a polypeptide; and

an active agent covalently attached to said polypeptide, wherein said active agent is an antiviral.

76. (New) The composition of claim 75 wherein said antiviral is selected from the group consisting of abacavir sulfate, Acyclovir, adefovir dipivoxil, alpha 1 proteinase inhibitor, amprenavir, BCX CW1812, didanosine, efavirenz, emivirine, famciclovir, ganciclovir, indinavir sulfate, interferon alfacon-1, lamivudine, lamivudine/zidovudine, nelfinavir mesylate, nevirapine pleconaril, ribavirin/peginterferon alfa-2b, Rimantadine HCl, ritonavir, saquinavir, sevirumab stavudine, tenofovir disoproxil, Thymosin alpha, valacyclovir hydrochloride and zidovudine.

77. (New) A composition comprising:

_____ a polypeptide; and

an active agent covalently attached to said polypeptide, wherein said active agent is a bone modulating drug.

78. (New) The composition of claim 77 wherein said bone modulating drug is selected from the group consisting of alendronate sodium, calcitriol, Etidronate disodium and pamidronate disodium.

79. (New) A composition comprising:

_____ a polypeptide; and

an active agent covalently attached to said polypeptide, wherein said active agent is an bronchodilator.

80. (New) The composition of claim 79 wherein said bronchodilator is selected from the group consisting of Albuterol, Formoterol, Ipratropium, montelukast sodium, montelukast/fexofenidine, terbutaline sulfate, Theophylline, zafirlukast, and A 78773.

81. (New) A composition comprising:

a polypeptide; and
an active agent covalently attached to said polypeptide, wherein said active agent is a cardiovascular drug.

82. (New) The composition of claim 81 wherein said cardiovascular drug is selected from the group consisting of antiangina agents, antiarrhythmic, ACE inhibitors, alpha-2 blockers, angiotensin II antagonists, beta blockers, calcium channel blockers, bosentan, BMS CW193884, BMS CW204352, conivaptan, candoxatril, Digoxin, L 159282, and milrinone lactate.

83. (New) The composition of claim 82 wherein said antiangina agent is selected from the group consisting of Isosorbide Dinitrate, Isosorbide Mononitrate, Nitroglycerin, and ranolazine hydrochloride.

84. (New) The composition of claim 82 wherein said antiarrhythmic is selected from the group consisting of Sotalol HCl and flecainide acetate.

85. (New) The composition of claim 82 wherein said ACE inhibitor is selected from the group consisting of Benazepril, Captopril, Enalapril, enalapril maleate/ hydrochlorothiazide, Fosinopril, Lisinopril, lisinopril/hydrochlorothiazide, moexepil hydrochloride, quinapril hydrochloride, Ramipril, andtrandolapril.

86. (New) The composition of claim 82 wherein said alpha-2 blocker is selected from the group consisting of doxazocin, prazosin, and terazocin.

87. (New) The composition of claim 82 wherein said angiotensin II antagonist is selected from the group consisting of Irbesartan, losartan potassium, losartan potassium/hydrochlorothiazide (HCTZ), Valsartan, and valsartan/HCTZ.

88. (New) The composition of claim 82 wherein said beta blocker is selected from the group consisting of Atenolol, Bisoprolol/HCTZ, candesartan cilexetil, , cavedilol, esatenolol, Labetalol HCl, metoprolol succinate, Nadolol, and Propranolol HCl.

89. (New) The composition of claim 82 wherein said calcium channel blocker is selected from the group consisting of amlodipine besylate, amlodipine besylate with benazepril HCl, BMS 189921, diltiazem, Felodipine, Isradipine, nifedipine, nisoldipine, and verapamil.

90. (New) A composition comprising:

_____ a polypeptide; and

an active agent covalently attached to said polypeptide, wherein said active agent is a cough suppressant.

91. (New) The composition of claim 90 wherein said cough suppressant is selected from the group consisting of dextromethorphan, Codeine/promethazine,

Codeine/phenylephrine/promethazine, Codeine and guaifenesin, Codeine/guaifenesin/

pseudoephedrine, Homatropine methylbromide/hydrocodone bitartrate

Hydrocodone bitartrate/phenylpropanolamine, Chlorpheniramine maleate/hydrocodone

bitartrate, and pseudoephedrine/Guaifenesin and hydrocodone, Chlorpheniramine polistirex and hydrocodone polystirex.

92. (New) A composition comprising:

_____ a polypeptide; and

an active agent covalently attached to said polypeptide, wherein said active agent is an diagnostic aid.

93. (New) The composition of claim 92 wherein said diagnostic aid is selected from the group consisting of gadodiamide, gadopentetate dimeglumine, gadoteridol, iodixanol, iopromide,

Ioxaglate meglumine and Ioxaglate sodium.

94. (New) A composition comprising:

_____ a polypeptide; and

an active agent covalently attached to said polypeptide, wherein said active agent is a diuretic.

95. (New) The composition of claim 94 wherein said diuretic is selected from the group consisting of Furosemide, Hydrochlorothiazide, Hydrochlorothiazide/ Triamterene, Metolazone, Spironolactone, toseamide and Triamterene.

96. (New) A composition comprising:

_____ a polypeptide; and

an active agent covalently attached to said polypeptide, wherein said active agent is a dopaminergic agent.

97. (New) The composition of claim 96 wherein said dopaminergic agent is selected from the group consisting of Bromocriptine, cabergoline, Carbidopa/Levodopa, ecopipam, Pergolide, pramipexole dihydrochloride, ropinirole hydrochloride, Selegiline HCl, Dopamine/D5W.

98. (New) A composition comprising:

_____ a polypeptide; and

an active agent covalently attached to said polypeptide, wherein said active agent is an enzyme inhibitor.

99. (New) The composition of claim 98 wherein said enzyme inhibitor is selected from the group consisting of befloxatone, cilastatin sodium, Cilomilast.

100. (New) A composition comprising:

_____ a polypeptide; and

an active agent covalently attached to said polypeptide, wherein said active agent is a gastrointestinal drugs.

101. (New) The composition of claim 100 wherein said gastrointestinal drug is selected from the group consisting of Proton Pump Inhibitors, H-2 antagonist, cisapride, dicyclomine HCl, GM 611, sucralfate and NE 0800.

102. (New) The composition of claim 101 wherein said Proton Pump Inhibitors is selected from the group consisting of lansoprazole, lansoprazole/amoxicillin/clarithromycin, omeprazole, and rabeprazole sodium.

103. (New) The composition of claim 101 wherein said H-2 antagonist is selected from the group consisting of cimetidine, famotidine, nizatidine, and ranitidine.

104. (New) A composition comprising:

_____ a polypeptide; and
_____ an active agent covalently attached to said polypeptide, wherein said active agent is a hematopoietic.

105. (New) The composition of claim 104 wherein said hematopoietic is selected from the group consisting of epoetin alfa recombinant, filgrastim, M-CSF (macrophage colony stimulating factor), sargramostim, and thrombopoietin.

106. (New) A composition comprising:

_____ a polypeptide; and
_____ an active agent covalently attached to said polypeptide, wherein said active agent is a replacement hormone or derivative thereof.

107. (New) The composition of claim 106 wherein said replacement hormone or derivative thereof is selected from the group consisting of abarelix, Adrenocorticotrophic hormone, the antiestrogenic EM 800, Conjugated Estrogens, Conjugated Estrogens/medroxyprogesterone acetate, desmopressin acetate, Esterified estrogens, Estropipate, ethinyl estradiol/norethindrone, Fludrocortisone acetate, Glucagon HCl, Goserelin, insulin lispro, Medroxyprogesterone Acetate, Methyltestosterone, NN 304, Norethindrone, paricalcitol, tabimorelin, tamsulosin hydrochloride, relaxin, Desogestrel/ethinyl estradiol, Ethinyl estradiol/Ethinodiol diacetate, Ethinyl estradiol/Levonorgestrel, Ethinyl estradiol/Norethindrone, Ethinyl estradiol/Norethindrone acetate, Ethinyl estradiol/Norgestimate, Ethinyl estradiol/Norgestrel, Ethinyl estradiol/Desogestrel and raloxifine hydrochloride.

108. (New) A composition comprising:

_____ a polypeptide; and

an active agent covalently attached to said polypeptide, wherein said active agent is a hypnotic.

109. (New) The composition of claim 108 wherein said hypnotic is selected from the group consisting of Phenobarbital, Temazepam, Zaleplon, and Zolpidem.

110. (New) A composition comprising:

_____ a polypeptide; and

an active agent covalently attached to said polypeptide, wherein said active agent is an immunomodulator.

111. (New) The composition of claim 110 wherein said immunomodulator is selected from the group consisting of Acitretin, ilodecakin, riluzole, LFA3TIP, and infliximab.

112. (New) A composition comprising:

_____ a polypeptide; and

an active agent covalently attached to said polypeptide, wherein said active agent is an immunosuppressant.

113. (New) The composition of claim 112 wherein said immunosuppressant is selected from the group consisting of azathioprine, BMS CW188667, Cyclosporine, methylprednisilone, mycophenolate mofetil, prednisone, and tacrolimus.

114. (New) A composition comprising:

_____ a polypeptide; and

an active agent covalently attached to said polypeptide, wherein said active agent is a lipid regulating drug.

115. (New) The composition of claim 114 wherein said lipid regulating drug is selected from the group consisting of atorvastatin calcium, avasimibe, cerivastatin sodium, and Colestipol HCl., Gemfibrozil, fluvastatin, fenofibrate, Lovastatin, pravastatin sodium, simvastatin, Phytosterol and 264W94.

116. (New) A composition comprising:

_____ a polypeptide; and
an active agent covalently attached to said polypeptide, wherein said active agent is an neurological agent.

117. (New) The composition of claim 116 wherein said neurological agent is selected from the group consisting of altinicline, Benzatropine Mesylate, Clomipramine, donepezil hydrochloride, galitramer acetate, interferon beta-1 α , lithium carbonate, mecasermin, naltrexone, remacemide, PD 1555U88 and tomoxetine, and xaliprodin.

118. (New) A composition comprising:

_____ a polypeptide; and
an active agent covalently attached to said polypeptide, wherein said active agent is an muscle relaxant.

119. (New) The composition of claim 118 wherein said muscle relaxant is selected from the group consisting of Baclofen, Carisoprodol, Cyclobenzaprine HCl, Metaxalone, and Orphenadrine citrate.

120. (New) A composition comprising:

_____ a polypeptide; and
an active agent covalently attached to said polypeptide, wherein said active agent is an neuromuscular blocking agent.

121. (New) The composition of claim 120 wherein said neuromuscular blocking agent is selected from the group consisting of cisatracurium besylate, mivacurium chloride, rocuronium bromide, and Vecuronium bromide.

122. (New) A composition comprising:

_____ a polypeptide; and
an active agent covalently attached to said polypeptide, wherein said active agent is a platelet anti-aggregation drug.

123. (New) The composition of claim 122 wherein said platelet anti-aggregation drug is selected from the group consisting of anagrelide hydrochloride, clopidogrel bisulfate, Dipyridamole, eptifibatide, ticlopidine hydrochloride, and tirofiban hydrochloride.

124. (New) A composition comprising:

_____ a polypeptide; and
an active agent covalently attached to said polypeptide, wherein said active agent is a stimulant/anorexient.

125. (New) The composition of claim 124 wherein said stimulant/anorexient is selected from the group consisting of amphetamine, caffiene, methylphenidate, orlistat, pemoline, and sibutramine HCl.

126. (New) A composition comprising:

_____ a polypeptide; and
an active agent covalently attached to said polypeptide, wherein said active agent is a thyroid drug.

127. (New) The composition of claim 126 wherein said thyroid drug is selected from the group consisting of iodothyronine, thyroxine (T4, levo and dextro) and liothyronine (T3, levo and dextro).

128. (New) A composition comprising:

_____ a polypeptide; and
an active agent covalently attached to said polypeptide, wherein said active agent is an urological drug.

129. (New) The composition of claim 128 wherein said urological drug is selected from the group consisting of tolterodine tartrate, finasteride, alprostadil, Bromocriptine, cabergoline, and sildenafil.

130. (New) A composition comprising:

_____ a polypeptide; and

an active agent covalently attached to said polypeptide, wherein said active agent is a vaccine.

131. (New) The composition of claim 130 wherein said vaccine is selected from the group consisting of recombinant hepatitis vaccine, and rotavirus vaccine.

132. (New) A composition comprising:

_____ a polypeptide; and

an active agent covalently attached to said polypeptide, wherein said active agent is a vitamin.

133. (New) The composition of claim 132 wherein said vitamin is selected from the group consisting of Daily Multi Vit, Vitamin B12, and Vitamin C.

134. (New) A composition comprising:

_____ a polypeptide; and

an active agent covalently attached to said polypeptide, wherein said active agent is selected from the group consisting of AGI 1067, ALT 711, amifostine, anaritide, arginine, CEB 925, CVT CW124, flumazenil, follitropin alfa/beta, gantofiban, gastrin CW17 immunogen, GT 102279, ilomastat, imiglucerase, Isotretinoin, Ketotifen, Leuprolide acetate, levocarnitine, lintuzumab, megestrol acetate, mesna, Misoprostol, modafinil, naltrexone, nimodipine, oprelvekin, oxybutynin chloride, palivizumab, PD 135158, Pentoxifylline, poloxamer CW188, Propofol, prourokinase, Pseudoephedrine, repinotan, sevelamer hydrochloride, sinapultide sodium polystyrene sulfonate, teriparatide, thalidomide, tPA analogue, urokinase, Ursodiol, xaliproden, and zenarestat